Pharma stock soars 150% after injectables deal with Novo

Pharma stock soars 150% after injectables deal with Novo: the analysis positions LLY, PFE and SNY under pressure; confidence high.

Analyzed 2026-09-25 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Who's next

▼ LLY Eli Lilly — impact -55 · confidence high · horizon quarters · 2nd order
Eli Lilly faces weaker obesity demand as Novo's monthly injections erode tirzepatide's convenience advantage.
Chain: Novo gains monthly depot delivery option → Zepbound weekly dosing loses convenience edge → payers and patients favor fewer injections → Lilly incretin volume growth slows
What would break the call: Depot formulation shows worse tolerability in trials and Lilly's orforglipron launch takes share instead.
▼ PFE Pfizer — impact -46 · confidence medium · horizon quarters · 3rd order
Pfizer's long-acting injectable pipeline loses value as Novo's depot platform increases competing supply.
Chain: Novo secures depot delivery technology → monthly obesity dosing becomes competitive baseline → Pfizer obesity assets face higher bar → pipeline risk adjusted value declines
What would break the call: Pfizer reports competitive monthly amylin data that restores investor confidence in its obesity program.
▼ SNY Sanofi — impact -45 · confidence low · horizon weeks · 3rd order
Sanofi contends with lower sales volume for its competing injectable products due to Novo capacity expansion.
Chain: Novo expands long acting injectable capacity → competing chronic injectables face crowded market → Sanofi pricing power weakens in overlap areas → injectable franchise volume growth slows
What would break the call: Sanofi immunology growth accelerates and shows no share loss to metabolic injectable competitors.
▼ HIMS Hims & Hers Health — impact -34 · confidence low · horizon quarters · 2nd order
Hims markets compounded and personalized injectables that lose appeal against a branded monthly depot with proprietary delivery protection.
Chain: branded monthly depot enters obesity market → compounded weekly semaglutide loses convenience parity → Hims subscriber retention weakens → weight loss revenue growth slows
What would break the call: Hims expands its Novo partnership and adds branded depot distribution to its platform.
▼ EMBC Embecta — impact -32 · confidence low · horizon quarters · 2nd order
Embecta ships pen needles whose unit volumes fall as dosing frequency for injectable metabolic therapies drops sharply.
Chain: monthly depot dosing replaces weekly injections → pen needle units per patient fall → Embecta consumable volume declines → revenue and cash flow shrink
What would break the call: Overall injectable patient population expands fast enough to offset lower needles per patient.
▼ VKTX Viking Therapeutics — impact -31 · confidence medium · horizon weeks · 3rd order
Viking Therapeutics faces weaker partnership terms as monthly obesity injections make its weekly dosing less competitive.
Chain: monthly depot dosing becomes competitive standard → weekly subcutaneous assets look less differentiated → Viking partnership leverage weakens → deal terms and valuation compress
What would break the call: Viking announces a large partnership or oral data that sustains its standalone valuation.
▼ AMGN Amgen — impact -30 · confidence medium · horizon quarters · 3rd order
Amgen's MariTide loses differentiation as Novo's depot platform matches its monthly dosing.
Chain: Novo obtains monthly depot delivery capability → MariTide monthly dosing edge narrows → Amgen obesity launch economics weaken → pipeline contribution to valuation declines
What would break the call: MariTide phase 3 shows superior weight loss and tolerability that dosing parity cannot offset.
▼ GPCR Structure Therapeutics — impact -26 · confidence medium · horizon weeks · 3rd order
Structure Therapeutics loses its oral convenience advantage as monthly injections reduce the burden of obesity treatment.
Chain: monthly injection reduces patient dosing burden → oral pill convenience advantage narrows → Structure Therapeutics differentiation weakens → partnering and financing terms worsen
What would break the call: Aleniglipron delivers strong phase 2b weight loss with clean tolerability and oral demand stays intact.
▼ ABBV AbbVie — impact -25 · confidence low · horizon quarters · 3rd order
AbbVie revenue from injectable drugs declines as Novo deal accelerates competitive product launches in the market.
Chain: Novo deal accelerates depot injectable competition → obesity spending crowds payer formulary budgets → AbbVie injectable franchises face pricing pressure → specialty revenue growth moderates
What would break the call: AbbVie immunology scripts keep beating guidance and show no payer budget crowding effect.
▼ MRK Merck — impact -25 · confidence low · horizon quarters · 3rd order
Merck's oral GLP-1 entry loses appeal as monthly injections shrink the convenience gap for obesity patients.
Chain: monthly depot lowers injection burden → oral obesity pill advantage narrows → Merck licensed oral candidate faces tougher launch → expected obesity revenue contribution declines
What would break the call: Merck's oral candidate posts strong weight loss data and payers favor cheaper pill therapy.
▼ ALT Altimmune — impact -24 · confidence medium · horizon weeks · 3rd order
Altimmune faces a higher clinical bar as monthly depot therapies eliminate pemvidutide's dosing advantage.
Chain: monthly depot becomes dosing benchmark → pemvidutide weekly dosing loses relative appeal → Altimmune faces higher clinical and commercial bar → partnering value and financing terms deteriorate
What would break the call: Altimmune MASH data drive a partnership on liver disease where dosing frequency matters less.

Already moved

▲ VERU Veru — impact +92 · confidence low · horizon immediate · 1st order
Veru receives free Wegovy supply and a potential Novo licensing path, lowering trial costs while improving partnership value.
Chain: Novo signs injectables deal with Veru → Veru receives free Wegovy clinical supply → trial spending on drug supply falls → licensing option adds potential milestone revenue
What would break the call: Novo declines the license option after phase 3 data and Veru returns to dilutive equity funding.
▲ HALO Halozyme — impact +56 · confidence medium · horizon immediate · 2nd order
Halozyme increases delivery-platform royalties as Novo's successful injectable collaboration validates less frequent dosing.
Chain: deal validates less frequent injectable dosing → partners seek subcutaneous delivery enabling platforms → Halozyme licenses ENHANZE to more sponsors → royalty revenue base widens
What would break the call: A patent ruling or partner switch to a rival delivery platform cuts ENHANZE royalty guidance.
▲ OMER Omeros — impact +55 · confidence low · horizon immediate · 2nd order
Omeros licensed a program to Novo and benefits as investors reprice small caps holding Novo partnership optionality.
Chain: Novo signs licensing deals with small caps → market rewards Novo partnership optionality → Omeros existing Novo agreement gets revalued → upfront and milestone cash flows repriced
What would break the call: Novo terminates or deprioritizes the licensed program and milestone payments disappear from guidance.
▲ WST West Pharmaceutical Services — impact +52 · confidence low · horizon quarters · 2nd order
West supplies elastomer and containment components for depot formulations, and complex long-acting products carry higher per-unit component pricing.
Chain: Novo scales long acting depot injectables → depot products need specialized elastomer closures → West ships higher value containment components → component revenue and mix improve
What would break the call: Novo insources containment components or destocking at large customers cuts West order volumes again.
▲ STVN Stevanato — impact +48 · confidence low · horizon quarters · 2nd order
Stevanato sells specialized syringes and vials required for viscous depot suspensions, lifting order volumes from obesity drug makers.
Chain: depot obesity injectables enter development → viscous suspensions need specialized syringes and vials → Stevanato wins high value container orders → biopharma segment revenue accelerates
What would break the call: Novo standardizes on existing pen cartridges and Stevanato guides capacity expansion utilization lower.
▲ NVO Novo Nordisk — impact +41 · confidence medium · horizon quarters · 1st order
Novo Nordisk strengthens Wegovy's competitive position by securing long-acting delivery technology and adjunctive therapy rights.
Chain: Novo licenses depot injectable technology → Wegovy franchise gains monthly dosing path → adherence and payer positioning improve → semaglutide revenue defense strengthens
What would break the call: Depot program fails phase 2 or regulators demand additional safety work that delays filing.
▲ BDX Becton Dickinson — impact +40 · confidence medium · horizon quarters · 2nd order
Becton Dickinson gains injection-device revenue as Novo's depot obesity treatments expand demand for prefillable syringes and needles.
Chain: depot obesity injectables reach commercial scale → autoinjectors and prefillable syringes needed → Becton Dickinson pharmaceutical systems ships more units → device revenue grows
What would break the call: Fewer annual injections per patient reduce total needle units and BD cuts pharmaceutical systems guidance.
▲ ALKS Alkermes — impact +38 · confidence low · horizon weeks · 2nd order
Alkermes owns depot injectable formulation patents, and large upfront payments for such technology reset valuation benchmarks for its platform.
Chain: large payment made for depot delivery technology → market reprices long acting injectable platforms → Alkermes depot patent estate looks undervalued → partnership and royalty optionality rises
What would break the call: Alkermes signs no metabolic depot partnership and investors keep valuing it only on Vivitrol and orexin.
▲ TMO Thermo Fisher Scientific — impact +37 · confidence medium · horizon weeks · 2nd order
Thermo Fisher gains development and manufacturing revenue as Novo scales depot injectables from formulation through commercial production.
Chain: Novo scales depot injectable manufacturing → sterile fill finish and development capacity needed → Thermo Fisher wins pharma services contracts → CDMO revenue backlog grows
What would break the call: Novo uses only internal and Catalent owned sites and Thermo pharma services growth stays flat.
▲ DHR Danaher — impact +32 · confidence medium · horizon quarters · 2nd order
Danaher expands bioprocessing sales as manufacturers build sterile production lines for long-acting obesity injectables.
Chain: obesity injectable capacity buildout accelerates → bioprocessing consumables and filtration demand rises → Danaher biotechnology segment orders improve → revenue growth reaccelerates
What would break the call: Bioprocessing orders stay weak and Danaher guides biotechnology core growth below expectations again.
▲ RPRX Royalty Pharma — impact +30 · confidence low · horizon quarters · 3rd order
Royalty Pharma funds drug developers in exchange for royalties and gains as delivery platform deal values rise.
Chain: large payments for delivery technology rights → royalty and milestone assets reprice higher → Royalty Pharma portfolio marks improve → new funding deals priced attractively
What would break the call: Rising rates or a failed portfolio asset cut adjusted cash receipts guidance for the year.
▲ RGEN Repligen — impact +28 · confidence low · horizon quarters · 3rd order
Repligen sells filtration and purification hardware consumed when peptide and depot manufacturing capacity expands.
Chain: obesity drug capacity buildout continues → filtration and chromatography equipment ordered → Repligen consumables pull through rises → revenue growth improves
What would break the call: Capital spending at large pharma slows and Repligen cuts full year revenue guidance.
▲ TEVA Teva Pharmaceutical — impact +25 · confidence low · horizon quarters · 2nd order
Teva runs long acting injectable technology and sterile capacity that gains value as depot platforms are repriced.
Chain: depot injectable platforms command large payments → Teva long acting portfolio gains perceived value → sterile capacity attracts partnering interest → innovative medicines revenue outlook improves
What would break the call: Teva books no metabolic partnership and generic price erosion dominates the earnings narrative.
▲ AMPH Amphastar Pharmaceuticals — impact +22 · confidence low · horizon quarters · 2nd order
Amphastar operates sterile injectable capacity that large partners increasingly rent as depot manufacturing demand outstrips internal plants.
Chain: depot manufacturing demand exceeds internal plants → sponsors rent external sterile injectable capacity → Amphastar sells contract manufacturing slots → utilization and contract revenue rise
What would break the call: Amphastar dedicates capacity to its own generics and signs no new depot manufacturing contracts.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Mixed	VERU	+0.7% vs SPY
5 trading days	Mixed	VERU	+1.6% vs SPY

Related scenarios

Stocks in this scenario

LLY · PFE · SNY · HIMS · EMBC · VKTX · AMGN · GPCR · ABBV · MRK · ALT · VERU · HALO · OMER · WST · STVN · NVO · BDX · ALKS · TMO · DHR · RPRX · RGEN · TEVA · AMPH

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario